Wall Street analysts expect Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) to post $39.94 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $30.90 million and the highest estimate coming in at $53.00 million. Blueprint Medicines […]
Nomura Asset Management Co. Ltd. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 20.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 29,935 shares of the biotechnology company’s stock after purchasing an additional 5,172 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Blueprint Medicines were worth […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating)‘s stock had its “buy” rating restated by research analysts at JMP Securities in a research report issued on Monday, TipRanks reports. They presently have a $152.00 price target on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 132.20% from the company’s previous close. […]
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $66.51, but opened at $69.23. Blueprint Medicines shares last traded at $69.03, with a volume of 551 shares trading hands. Several research analysts recently weighed in on BPMC shares. Morgan Stanley […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm presently has a $68.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside […]